본문 바로가기
KERD
논문KCI 등재

Role of Local Treatment for Oligometastasis: A Comparability Based Meta-Analysis

김경환|임채홍|조원경|이종훈|안용찬|김영석|지의규|서양권
대한암학회 (Korean Cancer Association)|2022.10|Cancer Research and Treatment|제54권 제4호|pp. 953-969|DOI 10.4143/crt.2022.329

3

조회

0

다운로드

8

인용

0

참고문헌

키워드

Meta-analysisRadiotherapySurgeryLocal therapyOligometastasis
주제분류의학일반

초록

Purpose: We intend to investigate the oncological efficacy and feasibility of local consolidative therapy (LCT) through a meta-analysis method. Materials and methods: Four databases including PubMed, MEDLINE, Embase, and Cochrane library were searched. Target studies are controlled trials comparing outcomes of LCT versus a control group. Primary endpoints are overall survival (OS) and progression-free survival (PFS). Results: A total of 54 studies involving 7,242 patients were included. Pooled analyses showed that the LCT arm could achieve improved OS with pooled odds ratio of 2.896 (95% confidence interval [CI], 2.377 to 3.528; p < 0.001). Regarding PFS, pooled analyses showed pooled odds ratio of 3.045 (95% CI, 2.356 to 3.937; p < 0.001) in favor of the LCT arm. In the subgroup analyses including the studies with reliable comparability (e.g. randomized studies or intentionally matched studies without significant favorable prognosticator in LCT arms), pooled odds ratio was 2.548 (95% CI, 1.808 to 3.591; p < 0.001) favoring the LCT arm regarding OS. Regarding PFS, pooled OR was 2.656 (95% CI, 1.713 to 4.120; p < 0.001) which also favored the LCT arm. Subgroup analyses limited to the randomized controlled trials (RCT) were also performed and pooled odds ratios on OS and PFS were 1.535 (95% CI, 1.082 to 2.177; p=0.016) and 1.668 (95% CI, 1.187 to 2.344; p=0.003). The rates of grade ≥ 3 complications related to LCT was mostly low (< 10%) and not significantly higher compared to the control arm. Conclusion: Pooled analyses results of all included studies, selected studies with reliable comparability, and RCT's demonstrated the survival benefit of LCT. These consistent results suggest that LCT was beneficial to the patients with oligometastasis.

Abstract

Purpose: We intend to investigate the oncological efficacy and feasibility of local consolidative therapy (LCT) through a meta-analysis method. Materials and methods: Four databases including PubMed, MEDLINE, Embase, and Cochrane library were searched. Target studies are controlled trials comparing outcomes of LCT versus a control group. Primary endpoints are overall survival (OS) and progression-free survival (PFS). Results: A total of 54 studies involving 7,242 patients were included. Pooled analyses showed that the LCT arm could achieve improved OS with pooled odds ratio of 2.896 (95% confidence interval [CI], 2.377 to 3.528; p < 0.001). Regarding PFS, pooled analyses showed pooled odds ratio of 3.045 (95% CI, 2.356 to 3.937; p < 0.001) in favor of the LCT arm. In the subgroup analyses including the studies with reliable comparability (e.g. randomized studies or intentionally matched studies without significant favorable prognosticator in LCT arms), pooled odds ratio was 2.548 (95% CI, 1.808 to 3.591; p < 0.001) favoring the LCT arm regarding OS. Regarding PFS, pooled OR was 2.656 (95% CI, 1.713 to 4.120; p < 0.001) which also favored the LCT arm. Subgroup analyses limited to the randomized controlled trials (RCT) were also performed and pooled odds ratios on OS and PFS were 1.535 (95% CI, 1.082 to 2.177; p=0.016) and 1.668 (95% CI, 1.187 to 2.344; p=0.003). The rates of grade ≥ 3 complications related to LCT was mostly low (< 10%) and not significantly higher compared to the control arm. Conclusion: Pooled analyses results of all included studies, selected studies with reliable comparability, and RCT's demonstrated the survival benefit of LCT. These consistent results suggest that LCT was beneficial to the patients with oligometastasis.

참고문헌 (76)

  1. Barney JD, "Adenocarcinoma of the kidney with metastasis to the lung : cured by nephrectomy and lobectomy", J Urol, 42, pp.269~276 (1939)
  2. Nordlinger B, "Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie", Cancer, 77, pp.1254~1262 (1996)
  3. Pastorino U, "Long-term results of lung metastasectomy : prognostic analyses based on 5206 cases", J Thorac Cardiovasc Surg, 113, pp.37~49 (1997)
  4. Chalkidou A, "Stereotactic ablative body radiotherapy in patients with oligometastatic cancers : a prospective, registry-based, single-arm, observational, evaluation study", Lancet Oncol, 22, pp.98~106 (2021)
  5. Lievens Y, "Defining oligometastatic disease from a radiation oncology perspective : an ESTRO-ASTRO consensus document", Radiother Oncol, 148, pp.157~166 (2020)
  6. Phillips R, "Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer : the ORIOLE phase 2 randomized clinical trial", JAMA Oncol, 6, pp.650~659 (2020)
  7. Palma DA, "Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers : long-term results of the SABR-COMET phase II randomized trial", J Clin Oncol, 38, pp.2830~2838 (2020)
  8. Gomez DR, "Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy : a multicentre, randomised, controlled, phase 2 study", Lancet Oncol, 17, pp.1672~1682 (2016)
  9. Lehrer EJ, "Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer : a systematic review and meta-analysis", JAMA Oncol, 7, pp.92~106 (2021)
  10. Jingu K, "Stereotactic radiotherapy for pulmo-nary oligometastases from colorectal cancer : a systematic review and meta-analysis", Technol Cancer Res Treat, 17, pp.1533033818794936~ (2018)
  11. Moher D, "PRISMA statement", Epidemiology, 22, pp.128~ (2011)
  12. Higgins JP, "Cochrane handbook for systematic reviews of interventions" (2019), John Wiley & Sons
  13. Reeves BC, "Cochrane handbook for systematic reviews of interventions", pp.595~620 (2019), John Wiley & Sons
  14. Shin IS, "Stepwise-hierarchical pooled analysis for synergistic interpretation of meta-analyses involving randomized and observational studies : methodology development", J Med Internet Res, 23, pp.e29642~ (2021)
  15. "The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses" (2011)[URL]
  16. Cochran WG, "The combination of estimates from different experiments", Biometrics, 10, pp.101~129 (1954)
  17. Higgins JP, "Quantifying heterogeneity in a meta-analysis", Stat Med, 21, pp.1539~1558 (2002)
  18. Egger M, "Bias in meta-analysis detected by a simple, graphical test", BMJ, 315, pp.629~634 (1997)
  19. Duval S, "Trim and fill : a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis", Biometrics, 56, pp.455~463 (2000)
  20. fluoromethylcholine PET, "CT", Clin Genitourin Cancer, 15, pp.e773~e782 (2017)
  21. Chen J, "Sorafenib monotherapy versus sorafenib combined with regional therapies for hepatocellular carcinoma patients with pulmonary oligometastases : a propensity score-matched analysis", J Cancer, 9, pp.1745~1753 (2018)
  22. Chen Y, "Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases", J Thorac Dis, 11, pp.1536~1545 (2019)
  23. Depypere LP, "Palliative esophagectomy in unexpected metastatic disease : sense or nonsense?", Asian Cardiovasc Thorac Ann, 26, pp.552~557 (2018)
  24. Falk AT, "Effect on survival of local ablative treatment of metastases from sarcomas : a study of the French sarcoma group", Clin Oncol(R Coll Radiol), 27, pp.48~55 (2015)
  25. Frost N, "Local ablative treatment for synchronous single organ oligometastatic lung cancer : a propensity score analysis of 180 patients", Lung Cancer, 125, pp.164~173 (2018)
  26. Giessen C, "Evaluation of prognostic factors in liver-limited metastatic colorectal cancer : a preplanned analysis of the FIRE-1 trial", Br J Cancer, 109, pp.1428~1436 (2013)
  27. Gomez DR, "maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer : long-term results of a multi-institutional, phase II, randomized study", J Clin Oncol, 37, pp.1558~1565 (2019)
  28. Gore EM, "Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer(ED SCLC) : NRG Oncology RTOG 0937", J Thorac Oncol, 12, pp.1561~1570 (2017)
  29. Gray PJ, "Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival", Lung Cancer, 85, pp.239~244 (2014)
  30. He J, "Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis", World J Surg Oncol, 15, pp.36~ (2017)
  31. Hu F, "Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations", Clin Lung Cancer, 20, pp.e81~e90 (2019)
  32. Iyengar P, "Consolidative radiotherapy for limited metastatic non-small-cell lung cancer : a phase 2 randomized clinical trial", JAMA Oncol, 4, pp.e173501~ (2018)
  33. Lan T, "Oncological outcome of cytoreductive radical prostatectomy in prostate cancer patients with bone oligometastases", Urology, 131, pp.166~175 (2019)
  34. Morino K, "Proposed definition for oligometastatic recurrence in biliary tract cancer based on results of locoregional treatment : a propensity-score-stratified analysis", Ann Surg Oncol, 27, pp.1908~1917 (2020)
  35. Ni Y, "Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment", J Cancer Res Clin Oncol, 146, pp.197~203 (2020)
  36. Ost P, "Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence : a prospective, randomized, multicenter phase II trial", J Clin Oncol, 36, pp.446~453 (2018)
  37. Pan T, "Percutaneous CT-guided radiofrequency ablation for lymph node oligometastases from hepatocellular carcinoma : a propensity score-matching analysis", Radiology, 282, pp.259~270 (2017)
  38. Parker CC, "Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer(STAMPEDE) : a rando-mised controlled phase 3 trial", Lancet, 392, pp.2353~2366 (2018)
  39. Ruers T, "Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial", J Natl Cancer Inst, 109, pp.djx015~ (2017)
  40. Ruo L, "Elective bowel resection for incurable stage IV colorectal cancer : prognostic variables for asymptomatic patients", J Am Coll Surg, 196, pp.722~728 (2003)
  41. Schulz D, "Improved overall survival in head and neck cancer patients after specific therapy of distant metastases", Eur Arch Otorhinolaryngol, 275, pp.1239~1247 (2018)
  42. Shang S, "Local therapy combined with chemotherapy versus chemotherapy for postoperative oligometastatic non-small-cell lung cancer", Future Oncol, 15, pp.1593~1603 (2019)
  43. Sheu T, "Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy", Int J Radiat Oncol Biol Phys, 90, pp.850~857 (2014)
  44. Song YQ, "Treatment patterns and survival after 18F-fluorodeoxyglucose positron emission tomography", computed tomography-guided local consolidation therapy for oligometastatic non-small cell lung cancer : a two-center propensity score-matched analysis, 2020, pp.146, 1021~1031
  45. Steuber T, "Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment : a multi-institutional case-control study", Eur Urol Focus, 5, pp.1007~1013 (2019)
  46. Tsumura H, "Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer : a retrospective cohort study", Prostate, 79, pp.506~514 (2019)
  47. Xu LM, "Thoracic radiotherapy(TRT)improved survival in both oligo-and polymetastatic extensive stage small cell lung cancer", Sci Rep, 7, pp.9255~ (2017)
  48. Xu Q, "Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs", J Thorac Oncol, 13, pp.1383~1392 (2018)
  49. Yano T, "Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer", J Surg Oncol, 102, pp.852~855 (2010)
  50. Boeri L, "Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care : a single-center experience", Prostate Cancer Prostatic Dis, 24, pp.514~523 (2021)
  51. Chen XR, "Management of non-small-cell lung cancer patients initially diagnosed with 1 to 3 synchronous brain-only metastases : a retrospective study", Clin Lung Cancer, 22, pp.e25~e34 (2021)
  52. Deek MP, "Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in oligoprogressive castration-resistant prostate cancer", Eur Urol Oncol, 4, pp.447~455 (2021)
  53. Gauvin C, "Survival impact of aggressive treatment and PD-L1 expression in oligometastatic NSCLC", Curr Oncol, 28, pp.593~605 (2021)
  54. Hsu KH, "Primary tumor radiotherapy during EGFR-TKI disease control improves survival of treatment naive advanced EGFR-mutant lung adenocarcinoma patients", Onco Targets Ther, 14, pp.2139~2148 (2021)
  55. Hu X, "Efficacy and safety of local radiotherapy to all oligometastatic sites in elderly patients with metachronous oligometastatic cancers after initial teatment for the primary tumor", Cancer Manag Res, 13, pp.9247~9259 (2021)
  56. Ji X, "Clinical effects of stereotactic body radiation therapy targeting the primary tumor of liver-only oligometastatic pancreatic cancer", Front Oncol, 11, pp.659987~ (2021)
  57. Kagawa Y, "Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer", Cancer Sci, 111, pp.4442~4452 (2020)
  58. Kim K, "Efficacy of local rherapy for oligometastatic hepatocellular carcinoma : a propensity score matched analysis", J Hepatocell Carcinoma, 8, pp.35~44 (2021)
  59. Lan B, "Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China", Int J Cancer, 147, pp.3199~3205 (2020)
  60. Li H, "Combination of brachytherapy with iodine-125 seeds and systemic chemotherapy versus systemic chemotherapy alone for synchronous extracranial oligometastatic non-small cell lung cancer", Cancer Manag Res, 12, pp.8209~8220 (2020)
  61. Li J, "Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer", Radiother Oncol, 154, pp.201~206 (2021)
  62. Li W, "Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver : propensity score matching analysis", Oncotarget, 8, pp.52132~52141 (2016)
  63. Liu Y, "Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma : extent of tumor burden eradicated by radiotherapy", World J Urol, 39, pp.4183~4190 (2021)
  64. Moretto R, "Oligometastatic colorectal cancer : prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest", Eur J Cancer, 139, pp.81~89 (2020)
  65. Shao Y, "Feasibility of pancreaticoduodenectomy with synchronous liver metastasectomy for oligometastatic pancreatic ductal adeno-carcinoma : a case-control study", Ann Med Surg(Lond), 62, pp.490~494 (2021)
  66. Shi Z, "Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma : A propensity score matching and landmark analyses", Radiother Oncol, 164, pp.236~244 (2021)
  67. Wang P, "Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer", J Cancer Res Clin Oncol, 148, pp.1253~1261 (2022)
  68. Wang H, "Oligorecurrence non-small cell lung cancer after failure of first-line chemotherapy: computed tomography-guided (125)I seed implantation vs. second-line chemotherapy", Front Oncol, 10, pp.470~ (2020)
  69. Wright CM, "Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery", Oral Oncol, 121, pp.105509~ (2021)
  70. Yildirim BA, "Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate", Strahlenther Onkol, 195, pp.872~881 (2019)
  71. Zhao Y, "Systemic therapy plus thermal ablation versus systemic therapy alone for oligometastatic liver metastases from non-small cell lung cancer", Cardiovasc Intervent Radiol, 43, pp.1285~1293 (2020)
  72. Correa RJ, "Stereotactic body radiotherapy for oligometastasis : opportunities for biology to guide clinical management", Cancer J, 22, pp.247~256 (2016)
  73. Palma DA, "The oligometastatic state : separating truth from wishful thinking", Nat Rev Clin Oncol, 11, pp.549~557 (2014)
  74. Shin IS, "Updating perspectives on meta-analyses in the field of radiation oncology", Medicina(Kaunas), 57, pp.117~ (2021)
  75. Shrier I, "Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles", Am J Epidemiol, 166, pp.1203~1209 (2007)
  76. Beckham TH, "Metastasis-directed therapy for oligometastasis and beyond", Br J Cancer, 124, pp.136~141 (2021)

관련 논문AI추천

Top Ten Lessons Learned from Trials in Oligometastatic CancersDavid A. Palma, Vivian S. Tan대한암학회 · Cancer Research and Treatment2023 · 제55권 제1호Tumor Control and Overall Survival after Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer: a Meta-Analysis강기문, 권오영, 송진호, 정배권, 정호진, 최훈식, 하인봉대한암학회 · Cancer Research and Treatment2020 · 제52권 제4호The Clinical Efficacy of Colorectal Cancer Patients with Pulmonary Oligometastases by Sterotactic Body Ablative Radiotherapy: A Meta-Analysis안용찬, 유규상, 이종훈, 임채홍, 정재욱, 조원경, 지의규대한암학회 · Cancer Research and Treatment2024 · 제56권 제3호Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma김경환, 김혜련, 양고운, 윤홍인, 이창걸, 조연아, 홍민희대한암학회 · Cancer Research and Treatment2024 · 제56권 제1호Metastasis-Directed Local Therapy of Hepatic Oligometastasis from Colorectal Cancer and Future Perspective in Radiation Therapy안용찬, 엄준원, 유규상, 이종훈, 임채홍, 정재욱, 조원경, 조현민, 지의규대한암학회 · Cancer Research and Treatment2023 · 제55권 제3호Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies During Tyrosine Kinase Inhibitor Treatment김상위, 윤신교, 이대호, 이재철, 장윤정, 지원준, 최창민, 현동곤대한암학회 · Cancer Research and Treatment2023 · 제55권 제2호

이 간행물의 다른 논문 (30건)

Treating Oligometastses, Prelude or Just Hassles of Systemic Treatment이대호pp. 951-952Reclassification of Five BRCA1/2 Variants with Unknown Significance Using Complex Functional StudyAnikó Bozsik, János Papp, Vince Kornél Grolmusz, Attila Patócs, Edit Oláh, Henriett Butzpp. 970-984Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion천성민, 최창민, 지원준, 이재철, 김연주pp. 985-995The Value of the Illness-Death Model for Predicting Outcomes in Patients with Non‒Small Cell Lung Cancer정원기, 김진흠, 최혜미, 채금주pp. 996-1004A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer김동하, 최창민, 고대현, 김상엽, 김용만, 지원준, 최명근, 김어진, 정재섭, 노진경, 이재철, 도은주, 강윤미, 조용희pp. 1005-1016
원문 보기